Platinum-based anticancer agents: Innovative design strategies and biological perspectives
Publication in refereed journal

香港中文大學研究人員

引用次數
替代計量分析
.

其它資訊
摘要The impact of cisplatin on cancer chemotherapy cannot be denied. Over the past 20 years, much effort has been dedicated to discover new platinum-based anticancer agents that are superior to cisplatin or its analogue, carboplatin. Most structural modifications are based on changing one or both of the ligand types coordinated to platinum. Altering the leaving group can influence tissue and intracellular distribution of the drug, whereas the carrier ligand usually determines the structure of adducts formed with DNA. DNA-Pt adducts produced by cisplatin and many of its classical analogues are almost identical, and would explain their similar patterns of tumor sensitivity and susceptibility to resistance. Recently some highly innovative design strategies have emerged, aimed at overcoming platinum resistance and/or to introduce novel mechanisms of antitumor action. Platinum compounds bearing the 1,2-diaminocyclohexane carrier ligand; and those of multinuclear Pt complexes giving rise to radically different DNA-Pt adducts, have resulted in novel anticancer agents capable of circumventing cisplatin resistance. Other strategies have focused on integrating biologically active ligands with platinum moieties intended to selectively localizing the anticancer properties. With the rapid advance in molecular biology, combined with innovation, it is possible new Pt-based anticancer agents will materialize in the near future. (C) 2003 Wiley Periodicals, Inc.
著者Ho YP, Au-Yeung SCF, To KKW
期刊名稱Medicinal Research Reviews
出版年份2003
月份9
日期1
卷號23
期次5
出版社JOHN WILEY & SONS INC
頁次633 - 655
國際標準期刊號0198-6325
語言英式英語
關鍵詞anticancer agents; demethylcantharidin; inhibition; platinum complexes; protein phosphatase
Web of Science 學科類別Chemistry, Medicinal; CHEMISTRY, MEDICINAL; Pharmacology & Pharmacy; PHARMACOLOGY & PHARMACY

上次更新時間 2021-12-01 於 23:19